-
A/R Liquidation: Learn why CMS and OIG are monitoring skin substitute products, key billing compliance risks, ASP documentation requirements and audit prevention strategies.
-
Local Coverage Determination (Lc: Implementing structured protocols for local coverage determination (lc directly mitigates documentation discrepancies and streamlines claim submission.
-
5 Core Reasons For Heightened Cm: Targeting operational vulnerabilities in 5 core reasons for heightened cm protects practice cash flow and elevates first-pass claim acceptance rates.
-
Revenue Cycle Acceleration: Partnering with specialized RCM billing experts eliminates administrative backlog, shortens payment cycles, and safeguards practice revenue.
On April 11, the Centers for Medicare & Medicaid Services (CMS) announced that it is actively reviewing its coverage policies for skin substitute products. As a direct result of this ongoing national review, the effective date for the final Local Coverage Determination (LCD) regarding Skin Substitute Grafts and Cellular and Tissue-Based Products (CTP) for the treatment of diabetic foot ulcers and venous leg ulcers has been officially postponed to January 1, 2026.
What is Local Coverage Determination (LCD)? 5 Core Reasons for Heightened CMS & OIG Scrutiny 1. Absence of Independent Clinical Research 2. Non-Compliance with Average Sales Price (ASP) Data 3. Fraud Detection & Coding Pitfalls in Medical Billing 4. Patient Safety & Minimally Manipulated Tissues Proactive Audit Prevention with Shoreline RCM Frequently Asked Questions (FAQs)
-
LCD Implementation Delayed: Final MAC local coverage determination rules are deferred to January 1, 2026, granting practices time to align clinical workflows. -
ASP Scrutiny: OIG identified that 30 out of 68 HCPCS skin substitute codes lacked manufacturer-reported ASP data, triggering heavy reimbursement audits. -
Wound Size Alignment: Billed square centimeters must exactly match pre-application wound measurements and wastage logs to avoid clawbacks. -
Pre-Claim Validation: Continuous medical record pre-audits ensure full medical necessity documentation before claims submission to Medicare Part B.
What is Local Coverage Determination (LCD)?
A Local Coverage Determination (LCD) refers to the official decision made by a Medicare Administrative Contractor (MAC) governing whether a particular medical service, surgical procedure, or medical device is reasonable, necessary, and covered within their specified geographic jurisdiction.
LCDs provide explicit clinical parameters, required pre-treatment conservative care timelines (such as 4 weeks of standard wound care before graft application), and precise billing guidance. They are designed to help healthcare practitioners, wound care centers, hospital outpatient departments (HOPDs), and suppliers determine if a specific skin substitute is medically essential and eligible for Part B reimbursement.
Because skin substitutes are billed under Medicare Part B as biologicals or devices rather than prescription pharmaceuticals, CMS requires verifiable Average Sales Price (ASP) data to establish fair reimbursement benchmarks and prevent excessive taxpayer expenditures.
5 Core Reasons for Heightened CMS & OIG Scrutiny
The Office of Inspector General (OIG) and CMS have established targeted oversight on Cellular and Tissue-Based Products (CTPs) due to rapid cost escalations, aggressive marketing, and inconsistent documentation. The five primary areas of concern include:
- Absence of Independent Clinical Research: Limited peer-reviewed validation outside manufacturer-funded trials.
- Non-Compliance with ASP Guidelines: Failure by certain product manufacturers to submit quarterly sales price data.
- Misuse and Overutilization: Applying high-cost biological grafts without exhausting conservative care regimens.
- Patient Safety & Regulatory Exemptions: Risks associated with 361 HCT/P products that bypass formal FDA premarket trials.
- Fraud Detection in Medical Coding: Discrepancies between wound dimensions, graft sizes, and billed units.
1. Absence of Proper Clinical Research
Skin substitute products refer to engineered medical devices, synthetic scaffolds, and biological grafts used to replace or augment damaged dermal layers. These products play a vital role in specialized wound care—particularly for patients suffering from refractory diabetic foot ulcers (DFUs), venous stasis ulcers (VLUs), deep burns, and severe surgical wounds.
However, regulatory bodies have highlighted that aside from papers authored or funded by skin grafting manufacturers, many commercially available products lack rigorous, independent comparative effectiveness research. Furthermore, clinical trials demonstrating clear superior outcomes over advanced modern moist wound dressings across broad patient populations remain limited.
2. Non-Compliance with Average Sales Price (ASP) Data
The utilization and commercial pricing of skin grafting materials have expanded exponentially over recent years, placing immense financial strain on Medicare trust funds. An OIG investigation revealed that multiple manufacturers failed to comply with statutory Average Sales Price (ASP) reporting mandates for skin substitute products.
Crucially, CMS was unable to calculate accurate ASP-based payment amounts for 30 out of 68 HCPCS skin substitute billing codes due to missing quarterly price submissions. Without statutory ASP data, Medicare cannot ensure fair pricing benchmarks, creating an uneven billing landscape vulnerable to overpayments and subsequent clawback audits.
3. Fraud Detection & Coding Pitfalls in Medical Billing
Coding and billing for skin substitutes is intricate and requires specialized multi-specialty RCM expertise. Payer audits frequently identify systemic billing errors that can trigger False Claims Act inquiries or civil monetary penalties:
Key Documentation Vulnerabilities Flagged by OIG
4. Patient Safety & Minimally Manipulated Tissues
While skin substitutes provide meaningful clinical benefits for non-healing wounds, biological materials derived from human tissue present inherent clinical considerations. Many human-derived tissue products are classified under Section 361 of the Public Health Service Act as “minimally manipulated” human cellular and tissue-based products (HCT/Ps) intended for homologous use.
Because these products do not undergo the traditional multi-phase FDA premarket clinical trial approval required for pharmaceuticals (Section 351), CMS and OIG prioritize patient safety, sterile handling compliance, and documented medical necessity above all else.
Proactive Audit Prevention with Shoreline RCM
Navigating CMS skin substitute scrutiny requires a proactive, compliant billing infrastructure. Shoreline Medical Billing conducts comprehensive, periodic clinical chart audits to verify that your wound measurements, debridement notes, application codes, and modifier selections withstand strict scrutiny from Recovery Audit Contractors (RAC) and Unified Program Integrity Contractors (UPIC).
With certified AAPC/AHIMA billing specialists and advanced billing analytics, Shoreline empowers wound care clinics, podiatrists, dermatologists, and surgical centers to maximize clean claim acceptance while remaining fully shielded against compliance risks.
